If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Komagataella as a model organism == In the last few years, Komagataella was investigated and identified as a good model organism with several advantages. First of all, Komagataella can be grown and used easily in lab. Like other widely used yeast models, it has relatively short life span and fast regeneration time. Moreover, some inexpensive culture media have been designed, so that Komagataella can grow quickly on them, with high cell density. Whole genome sequencing for Komagataella has been performed. The K. phaffii GS115 genome has been sequenced by the Flanders Institute for Biotechnology and Ghent University, and published in Nature Biotechnology. The genome sequence and gene annotation can be browsed through the ORCAE system. The complete genomic data allows scientists to identify homologous proteins and evolutionary relationships between other yeast species and Komagataella. In addition, all seven species were sequenced by 2022. Furthermore, Komagataella are single eukaryotic cells, which means researchers could investigate the proteins inside Komagataella. Then the homologous comparison to other more complicated eukaryotic species can be processed, to obtain their functions and origins. Another advantage of Komagataella is its similarity to the well-studied yeast model — Saccharomyces cerevisiae. As a model organism for biology, S. cerevisiae have been well studied for decades and used by researchers for various purposes throughout history.
OXT decreases pancreatic islet hypertrophy. OXT has antioxidant and anti-inflammatory effects. Pancreatic islet inflammation is an important factor in the pathogenesis of diabetes. The protection of β-cells from death is considered as a new therapeutic target. The hypoglycaemic effect, stimulatory effect on insulin secretion and sensitivity, and improvement of pancreatic islet cells after OXT administration, strongly suggested that OXT might be a therapeutic target for treating diabetes Deficits in OXT or its receptor developed hyperleptinemia and late-onset obesity with increases in abdominal fats and fasting plasma triglycerides The balance of leptin and adiponectin in diabetic patients can be used as a predictor of insulin resistance and a useful indicator for the choice of drug to treat diabetes mellitus Oxytocin levels:
=== Elections === The Paris Archives store two sets of records for male voters. The first covers voters in the capital from 1860 to 1870. The second lists voters in the Seine department whose registration status was modified (added or removed) between 1921 and 1939. These records are accessible online.
=== As a drug target === Glyoxalase I is a target for the development of pharmaceuticals against bacteria, protozoans (especially Trypanosoma cruzi and the Leishmania) and human cancer. Numerous inhibitors have been developed, most of which share the glutathione moiety. Among the most tightly binding family of inhibitors to the human enzyme are derivatives of S-(N-aryl-N-hydroxycarbamoyl)glutathione, most notably the p-bromophenyl derivative, which has a dissociation constant of 14 nM. The closest analog of the transition state is believed to be S-(N-hydroxy-N-p-iodophenylcarbamoyl)glutathione; the crystal structure of this compound bound to the human enzyme has been solved to 2 Å resolution (PDB accession code PDB: 1QIN). Experiments suggest that methylglyoxal is preferentially toxic to proliferating cells, such as those in cancer. Recent research demonstrates that GLO1 expression is upregulated in various human malignant tumors including metastatic melanoma.
While it has been shown that the ACD when performing the catalysis uses magnesium and ATP for the formation of the cross-links the specifics of the mechanism are uncertain. Though an interesting aspect of the cross-link formed in this case, is that it uses a non-terminal Glu to ligate to a non-terminal Lys, which seems to be rare in the process of forming an isopeptide bond. Though the chemistry of ACD is still to be resolved, it shows that isopeptide bond formation is not dependent simply on Asp/Asn for non-terminal isopeptide linkages between proteins. The final case to be looked is the curious case of the post translational modifications of microtubilin (MT). MT contains a wide array of post translational modifications; however the two of most regarded interest are polyglutamylation and polyglycylation. Both modifications are similar in the sense they are repeating stretches of the same amino acid fused to the side chain carboxyl group of glutamate at the c-terminal region of the MT. The enzymatic mechanisms are not fully fleshed out as not much is known about the polyglycating enzyme. In the case of polyglutamylation the exact mechanism is also unknown, but it does seem to be ATP-dependent. Though again there is a lack of clarity in regard to the enzymatic chemistry, there is still valuable insight in the formation of isopeptide bonds using the R-group carboxyl of Glu in conjunction with the N-terminal amino of the modifying peptides.
Sources: en.wikipedia.org
== Corporate culture == S. Truett Cathy was a devout Southern Baptist; his religious beliefs had a major impact on the company. The company's official statement of corporate purpose says that the business exists "To glorify God by being a faithful steward of all that is entrusted to us. To have a positive influence on all who come in contact with Chick-fil-A." Cathy opposed the company becoming public for religious and personal reasons. A company spokesperson said in 2012, "The Chick-fil-A culture and service tradition in our Restaurants is to treat every person with honor, dignity, and respect –regardless of their belief, race, creed, sexual orientation, or gender."
Locals are "Districts"; national convention meets quadrennially; headquarters in Pittsburgh; in 1979 had $120,000,000 in insurance; also sponsored outings, baseball games, etc. While originally for German men and women, by 1979 the Union was open to men and women of all ethnic backgrounds. In 1923 the Union had 54,000 members, 50,000 in 1965, and 37,000 in 1979. Improved Order, Knights of Pythias Independent Order of Red Men North American Swiss Alliance - Founded July 14, 1865, as the Grütli Bund der Vereinigten Staaten von Nord Amerika in Cincinnati. Became Nordamerikanishcher Schweizerbund in July 1911. National convention meets quadrennially, locals are called branches or lodges. Open to Swiss, Swiss descendants, or spouses of Swiss. Membership 2,000 in 1965, 4,000 in 1978 and 3,350 in 1994, about 10 to 15% are social, uninsured members. Periodical originally called Gruetlianer changed to Der Schweizer in 1911. Headquarters in Cleveland in 1979, but it was an "organization on wheels" moving to several places every few years in the late 19th century Schwarzer Ritter, Deutscher Orden - Claimed great antiquity, though in 1899 it was said to have been present in the United States for about 30 years. Active in New York, New Jersey, Pennsylvania, and the District of Columbia. Sons of Hermann United League of America Workmen's Benefit Fund - Founded as the Workmen's Sick and Death Benefit Fund in 1884, this organization was licensed to provide insurance in February 1899. The current name was adopted in 1939. Membership opened to non-Germans in 1976.
If a strut of nasal-septum cartilage proves too weak, then a rib cartilage strut can be applied to provide the adequate nasal support; afterwards, the strut is covered with onlay grafts. Absent alar cartilages can be replaced using all of the conchal cartilage from both ears; two strips, each 10 mm wide, are harvested from the antihelical fold, and then are applied as replacement alar wings. The surgeon attaches them to the anterior nasal spine, and to each side of the (pear-shaped) pyriform aperture; the remainder of the harvested conchal cartilage is applied as onlay grafts to augment the nasal tip. A nasal-tip lining defect is unusual, because of its midline location; yet, the reconstruction is with an anteriorly based septal mucosal flap that is rotated into place to provide adequate coverage and correction of the nasal lining defect. Vertical lobule division (VLD) is a common technique for nasal tip refinement, which involves the medial crural angle and the lateral crural angle. (d) Alar lobule defect The appropriate surgical management of an alar lobule defect depends upon the dimensions (length, width, depth) of the wound. Anatomically, the nasal skin and the underlying soft tissues of the alar lobule form a semi-rigid aesthetic subunit that forms the graceful curve of the alar rim, and provides unobstructed airflow through the nostrils, the anterior nares.
=== Commercial applications === Similar to other networking technologies that began with the defense sector, e.g., the Defense Advanced Research Projects Agency (DARPA) funding ARPANET, the precursor to the Internet, DASH7 is similarly suited to a wide range of applications in development or being deployed, including:
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.